nodes	percent_of_prediction	percent_of_DWPC	metapath
Alvimopan—Hypokalaemia—Ixabepilone—breast cancer	0.00967	0.015	CcSEcCtD
Alvimopan—Connective tissue disorder—Lapatinib—breast cancer	0.00958	0.0149	CcSEcCtD
Alvimopan—Connective tissue disorder—Fulvestrant—breast cancer	0.00881	0.0137	CcSEcCtD
Alvimopan—Malnutrition—Lapatinib—breast cancer	0.00849	0.0132	CcSEcCtD
Alvimopan—Back pain—Lapatinib—breast cancer	0.00821	0.0128	CcSEcCtD
Alvimopan—Indinavir—SLCO1B1—breast cancer	0.00807	0.269	CrCbGaD
Alvimopan—Anaemia—Lapatinib—breast cancer	0.00785	0.0122	CcSEcCtD
Alvimopan—Malnutrition—Fulvestrant—breast cancer	0.00781	0.0121	CcSEcCtD
Alvimopan—Malnutrition—Toremifene—breast cancer	0.0077	0.012	CcSEcCtD
Alvimopan—Back pain—Fulvestrant—breast cancer	0.00755	0.0117	CcSEcCtD
Alvimopan—Back pain—Toremifene—breast cancer	0.00745	0.0116	CcSEcCtD
Alvimopan—Urinary tract disorder—Ixabepilone—breast cancer	0.00726	0.0113	CcSEcCtD
Alvimopan—Connective tissue disorder—Ixabepilone—breast cancer	0.00722	0.0112	CcSEcCtD
Alvimopan—Anaemia—Fulvestrant—breast cancer	0.00722	0.0112	CcSEcCtD
Alvimopan—Urethral disorder—Ixabepilone—breast cancer	0.0072	0.0112	CcSEcCtD
Alvimopan—Urinary tract disorder—Letrozole—breast cancer	0.00683	0.0106	CcSEcCtD
Alvimopan—Connective tissue disorder—Letrozole—breast cancer	0.0068	0.0106	CcSEcCtD
Alvimopan—Urethral disorder—Letrozole—breast cancer	0.00678	0.0105	CcSEcCtD
Alvimopan—Indinavir—ABCC1—breast cancer	0.00667	0.222	CrCbGaD
Alvimopan—Back pain—Exemestane—breast cancer	0.00656	0.0102	CcSEcCtD
Alvimopan—Urinary tract disorder—Idarubicin—breast cancer	0.00649	0.0101	CcSEcCtD
Alvimopan—Urinary tract disorder—Raloxifene—breast cancer	0.00649	0.0101	CcSEcCtD
Alvimopan—Connective tissue disorder—Raloxifene—breast cancer	0.00645	0.01	CcSEcCtD
Alvimopan—Urethral disorder—Raloxifene—breast cancer	0.00644	0.01	CcSEcCtD
Alvimopan—Urethral disorder—Idarubicin—breast cancer	0.00644	0.01	CcSEcCtD
Alvimopan—Malnutrition—Ixabepilone—breast cancer	0.0064	0.00995	CcSEcCtD
Alvimopan—Urinary retention—Goserelin—breast cancer	0.00622	0.00967	CcSEcCtD
Alvimopan—Dyspepsia—Lapatinib—breast cancer	0.0061	0.00948	CcSEcCtD
Alvimopan—Malnutrition—Letrozole—breast cancer	0.00602	0.00937	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Lapatinib—breast cancer	0.00598	0.0093	CcSEcCtD
Alvimopan—Constipation—Lapatinib—breast cancer	0.00592	0.00921	CcSEcCtD
Alvimopan—Anaemia—Ixabepilone—breast cancer	0.00591	0.00919	CcSEcCtD
Alvimopan—Back pain—Anastrozole—breast cancer	0.00583	0.00906	CcSEcCtD
Alvimopan—Back pain—Letrozole—breast cancer	0.00583	0.00906	CcSEcCtD
Alvimopan—Malnutrition—Idarubicin—breast cancer	0.00572	0.00889	CcSEcCtD
Alvimopan—Flatulence—Raloxifene—breast cancer	0.00563	0.00876	CcSEcCtD
Alvimopan—Dyspepsia—Fulvestrant—breast cancer	0.00561	0.00872	CcSEcCtD
Alvimopan—Anaemia—Anastrozole—breast cancer	0.00557	0.00866	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Fulvestrant—breast cancer	0.0055	0.00855	CcSEcCtD
Alvimopan—Constipation—Fulvestrant—breast cancer	0.00545	0.00847	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Toremifene—breast cancer	0.00543	0.00844	CcSEcCtD
Alvimopan—Constipation—Toremifene—breast cancer	0.00538	0.00836	CcSEcCtD
Alvimopan—Urinary retention—Thiotepa—breast cancer	0.00532	0.00827	CcSEcCtD
Alvimopan—Anaemia—Idarubicin—breast cancer	0.00529	0.00822	CcSEcCtD
Alvimopan—Dyspepsia—Exemestane—breast cancer	0.00487	0.00757	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Exemestane—breast cancer	0.00478	0.00743	CcSEcCtD
Alvimopan—Constipation—Exemestane—breast cancer	0.00473	0.00736	CcSEcCtD
Alvimopan—Urinary tract disorder—Melphalan—breast cancer	0.00458	0.00712	CcSEcCtD
Alvimopan—Connective tissue disorder—Melphalan—breast cancer	0.00456	0.00708	CcSEcCtD
Alvimopan—Urethral disorder—Melphalan—breast cancer	0.00455	0.00707	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Ixabepilone—breast cancer	0.00451	0.00701	CcSEcCtD
Alvimopan—Urinary tract disorder—Goserelin—breast cancer	0.00447	0.00694	CcSEcCtD
Alvimopan—Constipation—Ixabepilone—breast cancer	0.00447	0.00694	CcSEcCtD
Alvimopan—Urethral disorder—Goserelin—breast cancer	0.00443	0.00689	CcSEcCtD
Alvimopan—Hypokalaemia—Mitoxantrone—breast cancer	0.0044	0.00683	CcSEcCtD
Alvimopan—Hypokalaemia—Irinotecan—breast cancer	0.0044	0.00683	CcSEcCtD
Alvimopan—Dyspepsia—Anastrozole—breast cancer	0.00433	0.00673	CcSEcCtD
Alvimopan—Dyspepsia—Letrozole—breast cancer	0.00433	0.00673	CcSEcCtD
Alvimopan—Hypokalaemia—Gemcitabine—breast cancer	0.00428	0.00666	CcSEcCtD
Alvimopan—Anaemia—Chlorambucil—breast cancer	0.00428	0.00665	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Anastrozole—breast cancer	0.00425	0.0066	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Letrozole—breast cancer	0.00425	0.0066	CcSEcCtD
Alvimopan—Constipation—Anastrozole—breast cancer	0.0042	0.00654	CcSEcCtD
Alvimopan—Constipation—Letrozole—breast cancer	0.0042	0.00654	CcSEcCtD
Alvimopan—Benazepril—MTHFR—breast cancer	0.00412	0.138	CrCbGaD
Alvimopan—Dyspepsia—Raloxifene—breast cancer	0.00411	0.00639	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Raloxifene—breast cancer	0.00403	0.00626	CcSEcCtD
Alvimopan—Back pain—Tamoxifen—breast cancer	0.00399	0.0062	CcSEcCtD
Alvimopan—Connective tissue disorder—Vinorelbine—breast cancer	0.00398	0.00619	CcSEcCtD
Alvimopan—Malnutrition—Goserelin—breast cancer	0.00394	0.00612	CcSEcCtD
Alvimopan—Anaemia—Vinblastine—breast cancer	0.00392	0.0061	CcSEcCtD
Alvimopan—Flatulence—Goserelin—breast cancer	0.00388	0.00603	CcSEcCtD
Alvimopan—Urinary tract disorder—Thiotepa—breast cancer	0.00382	0.00594	CcSEcCtD
Alvimopan—Anaemia—Tamoxifen—breast cancer	0.00381	0.00592	CcSEcCtD
Alvimopan—Back pain—Goserelin—breast cancer	0.00381	0.00592	CcSEcCtD
Alvimopan—Connective tissue disorder—Thiotepa—breast cancer	0.0038	0.00591	CcSEcCtD
Alvimopan—Urethral disorder—Thiotepa—breast cancer	0.00379	0.0059	CcSEcCtD
Alvimopan—Anaemia—Melphalan—breast cancer	0.00373	0.0058	CcSEcCtD
Alvimopan—Anaemia—Goserelin—breast cancer	0.00364	0.00566	CcSEcCtD
Alvimopan—Hypokalaemia—Paclitaxel—breast cancer	0.00358	0.00557	CcSEcCtD
Alvimopan—Malnutrition—Vinorelbine—breast cancer	0.00353	0.00548	CcSEcCtD
Alvimopan—Back pain—Vinorelbine—breast cancer	0.00341	0.0053	CcSEcCtD
Alvimopan—Malnutrition—Thiotepa—breast cancer	0.00337	0.00524	CcSEcCtD
Alvimopan—Dyspepsia—Chlorambucil—breast cancer	0.00333	0.00517	CcSEcCtD
Alvimopan—Connective tissue disorder—Irinotecan—breast cancer	0.00328	0.0051	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Chlorambucil—breast cancer	0.00326	0.00507	CcSEcCtD
Alvimopan—Anaemia—Vinorelbine—breast cancer	0.00326	0.00507	CcSEcCtD
Alvimopan—Back pain—Thiotepa—breast cancer	0.00326	0.00506	CcSEcCtD
Alvimopan—Urinary tract disorder—Gemcitabine—breast cancer	0.00321	0.005	CcSEcCtD
Alvimopan—Connective tissue disorder—Gemcitabine—breast cancer	0.0032	0.00497	CcSEcCtD
Alvimopan—Urethral disorder—Gemcitabine—breast cancer	0.00319	0.00496	CcSEcCtD
Alvimopan—Anaemia—Thiotepa—breast cancer	0.00311	0.00484	CcSEcCtD
Alvimopan—Urinary retention—Capecitabine—breast cancer	0.00307	0.00478	CcSEcCtD
Alvimopan—Constipation—Vinblastine—breast cancer	0.00296	0.0046	CcSEcCtD
Alvimopan—Dyspepsia—Tamoxifen—breast cancer	0.00296	0.0046	CcSEcCtD
Alvimopan—Hypokalaemia—Capecitabine—breast cancer	0.00294	0.00457	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Tamoxifen—breast cancer	0.0029	0.00452	CcSEcCtD
Alvimopan—Dyspepsia—Melphalan—breast cancer	0.0029	0.00451	CcSEcCtD
Alvimopan—Constipation—Tamoxifen—breast cancer	0.00288	0.00447	CcSEcCtD
Alvimopan—Flatulence—Irinotecan—breast cancer	0.00287	0.00446	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Melphalan—breast cancer	0.00284	0.00442	CcSEcCtD
Alvimopan—Ketoprofen—CXCL8—breast cancer	0.00283	0.0945	CrCbGaD
Alvimopan—Dyspepsia—Goserelin—breast cancer	0.00283	0.0044	CcSEcCtD
Alvimopan—Back pain—Mitoxantrone—breast cancer	0.00281	0.00437	CcSEcCtD
Alvimopan—Back pain—Irinotecan—breast cancer	0.00281	0.00437	CcSEcCtD
Alvimopan—Constipation—Goserelin—breast cancer	0.00275	0.00427	CcSEcCtD
Alvimopan—Back pain—Gemcitabine—breast cancer	0.00274	0.00426	CcSEcCtD
Alvimopan—Urinary tract disorder—Paclitaxel—breast cancer	0.00269	0.00418	CcSEcCtD
Alvimopan—Anaemia—Mitoxantrone—breast cancer	0.00269	0.00418	CcSEcCtD
Alvimopan—Anaemia—Irinotecan—breast cancer	0.00269	0.00418	CcSEcCtD
Alvimopan—Connective tissue disorder—Paclitaxel—breast cancer	0.00268	0.00416	CcSEcCtD
Alvimopan—Urethral disorder—Paclitaxel—breast cancer	0.00267	0.00415	CcSEcCtD
Alvimopan—Anaemia—Gemcitabine—breast cancer	0.00262	0.00407	CcSEcCtD
Alvimopan—Anaemia—Fluorouracil—breast cancer	0.00257	0.004	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Vinorelbine—breast cancer	0.00249	0.00386	CcSEcCtD
Alvimopan—Constipation—Vinorelbine—breast cancer	0.00246	0.00383	CcSEcCtD
Alvimopan—Dyspepsia—Thiotepa—breast cancer	0.00242	0.00376	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Thiotepa—breast cancer	0.00237	0.00369	CcSEcCtD
Alvimopan—Malnutrition—Paclitaxel—breast cancer	0.00237	0.00369	CcSEcCtD
Alvimopan—Constipation—Thiotepa—breast cancer	0.00235	0.00365	CcSEcCtD
Alvimopan—Flatulence—Paclitaxel—breast cancer	0.00234	0.00363	CcSEcCtD
Alvimopan—Back pain—Paclitaxel—breast cancer	0.00229	0.00357	CcSEcCtD
Alvimopan—Urinary tract disorder—Docetaxel—breast cancer	0.00228	0.00355	CcSEcCtD
Alvimopan—Connective tissue disorder—Docetaxel—breast cancer	0.00227	0.00353	CcSEcCtD
Alvimopan—Urethral disorder—Docetaxel—breast cancer	0.00226	0.00352	CcSEcCtD
Alvimopan—Urinary tract disorder—Capecitabine—breast cancer	0.00221	0.00343	CcSEcCtD
Alvimopan—Connective tissue disorder—Capecitabine—breast cancer	0.0022	0.00342	CcSEcCtD
Alvimopan—Anaemia—Paclitaxel—breast cancer	0.00219	0.00341	CcSEcCtD
Alvimopan—Urethral disorder—Capecitabine—breast cancer	0.00219	0.00341	CcSEcCtD
Alvimopan—Dyspepsia—Mitoxantrone—breast cancer	0.00209	0.00325	CcSEcCtD
Alvimopan—Dyspepsia—Irinotecan—breast cancer	0.00209	0.00325	CcSEcCtD
Alvimopan—Hypokalaemia—Epirubicin—breast cancer	0.00205	0.00319	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Irinotecan—breast cancer	0.00205	0.00319	CcSEcCtD
Alvimopan—Indinavir—CYP2D6—breast cancer	0.00205	0.0683	CrCbGaD
Alvimopan—Constipation—Irinotecan—breast cancer	0.00203	0.00316	CcSEcCtD
Alvimopan—Constipation—Mitoxantrone—breast cancer	0.00203	0.00316	CcSEcCtD
Alvimopan—Malnutrition—Docetaxel—breast cancer	0.00201	0.00313	CcSEcCtD
Alvimopan—Dyspepsia—Fluorouracil—breast cancer	0.002	0.00311	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Gemcitabine—breast cancer	0.002	0.0031	CcSEcCtD
Alvimopan—Constipation—Gemcitabine—breast cancer	0.00198	0.00307	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Fluorouracil—breast cancer	0.00196	0.00305	CcSEcCtD
Alvimopan—Malnutrition—Capecitabine—breast cancer	0.00195	0.00303	CcSEcCtD
Alvimopan—Back pain—Docetaxel—breast cancer	0.00194	0.00302	CcSEcCtD
Alvimopan—Flatulence—Capecitabine—breast cancer	0.00192	0.00298	CcSEcCtD
Alvimopan—Hypokalaemia—Doxorubicin—breast cancer	0.0019	0.00295	CcSEcCtD
Alvimopan—Back pain—Capecitabine—breast cancer	0.00188	0.00293	CcSEcCtD
Alvimopan—Anaemia—Docetaxel—breast cancer	0.00186	0.00289	CcSEcCtD
Alvimopan—Anaemia—Capecitabine—breast cancer	0.0018	0.0028	CcSEcCtD
Alvimopan—Indinavir—CYP3A4—breast cancer	0.00176	0.0586	CrCbGaD
Alvimopan—Dyspepsia—Paclitaxel—breast cancer	0.0017	0.00265	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Paclitaxel—breast cancer	0.00167	0.0026	CcSEcCtD
Alvimopan—Constipation—Paclitaxel—breast cancer	0.00166	0.00257	CcSEcCtD
Alvimopan—Urinary tract disorder—Methotrexate—breast cancer	0.00164	0.00256	CcSEcCtD
Alvimopan—Urethral disorder—Methotrexate—breast cancer	0.00163	0.00254	CcSEcCtD
Alvimopan—Urinary tract disorder—Epirubicin—breast cancer	0.00154	0.00239	CcSEcCtD
Alvimopan—Connective tissue disorder—Epirubicin—breast cancer	0.00153	0.00238	CcSEcCtD
Alvimopan—Urethral disorder—Epirubicin—breast cancer	0.00153	0.00237	CcSEcCtD
Alvimopan—Indinavir—ABCB1—breast cancer	0.00146	0.0488	CrCbGaD
Alvimopan—Malnutrition—Methotrexate—breast cancer	0.00145	0.00225	CcSEcCtD
Alvimopan—Ketoprofen—PTGS1—breast cancer	0.00145	0.0482	CrCbGaD
Alvimopan—Dyspepsia—Docetaxel—breast cancer	0.00144	0.00225	CcSEcCtD
Alvimopan—Urinary tract disorder—Doxorubicin—breast cancer	0.00142	0.00221	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Docetaxel—breast cancer	0.00142	0.0022	CcSEcCtD
Alvimopan—Connective tissue disorder—Doxorubicin—breast cancer	0.00142	0.0022	CcSEcCtD
Alvimopan—Urethral disorder—Doxorubicin—breast cancer	0.00141	0.0022	CcSEcCtD
Alvimopan—Constipation—Docetaxel—breast cancer	0.0014	0.00218	CcSEcCtD
Alvimopan—Back pain—Methotrexate—breast cancer	0.0014	0.00218	CcSEcCtD
Alvimopan—Dyspepsia—Capecitabine—breast cancer	0.0014	0.00217	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Capecitabine—breast cancer	0.00137	0.00213	CcSEcCtD
Alvimopan—Constipation—Capecitabine—breast cancer	0.00136	0.00211	CcSEcCtD
Alvimopan—Malnutrition—Epirubicin—breast cancer	0.00136	0.00211	CcSEcCtD
Alvimopan—Anaemia—Methotrexate—breast cancer	0.00134	0.00208	CcSEcCtD
Alvimopan—Flatulence—Epirubicin—breast cancer	0.00134	0.00208	CcSEcCtD
Alvimopan—Back pain—Epirubicin—breast cancer	0.00131	0.00204	CcSEcCtD
Alvimopan—Malnutrition—Doxorubicin—breast cancer	0.00125	0.00195	CcSEcCtD
Alvimopan—Anaemia—Epirubicin—breast cancer	0.00125	0.00195	CcSEcCtD
Alvimopan—Flatulence—Doxorubicin—breast cancer	0.00124	0.00192	CcSEcCtD
Alvimopan—Back pain—Doxorubicin—breast cancer	0.00121	0.00189	CcSEcCtD
Alvimopan—Anaemia—Doxorubicin—breast cancer	0.00116	0.0018	CcSEcCtD
Alvimopan—Dyspepsia—Methotrexate—breast cancer	0.00104	0.00162	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Methotrexate—breast cancer	0.00102	0.00159	CcSEcCtD
Alvimopan—Dyspepsia—Epirubicin—breast cancer	0.000974	0.00151	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Epirubicin—breast cancer	0.000956	0.00149	CcSEcCtD
Alvimopan—Constipation—Epirubicin—breast cancer	0.000947	0.00147	CcSEcCtD
Alvimopan—Dyspepsia—Doxorubicin—breast cancer	0.000902	0.0014	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000884	0.00137	CcSEcCtD
Alvimopan—Constipation—Doxorubicin—breast cancer	0.000876	0.00136	CcSEcCtD
Alvimopan—Ketoprofen—PTGS2—breast cancer	0.000827	0.0276	CrCbGaD
Alvimopan—Ketoprofen—ALB—breast cancer	0.000736	0.0246	CrCbGaD
Alvimopan—OPRD1—Signaling Pathways—E2F1—breast cancer	9.76e-05	0.000299	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—PIK3CB—breast cancer	9.72e-05	0.000297	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PAK1—breast cancer	9.69e-05	0.000296	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—TGFBR2—breast cancer	9.63e-05	0.000295	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TCF7L2—breast cancer	9.51e-05	0.000291	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ITPR1—breast cancer	9.47e-05	0.00029	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—AKT2—breast cancer	9.47e-05	0.00029	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ERBB4—breast cancer	9.41e-05	0.000288	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MMP3—breast cancer	9.41e-05	0.000288	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—STAT5A—breast cancer	9.41e-05	0.000288	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—PIK3CG—breast cancer	9.4e-05	0.000288	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—PIK3CB—breast cancer	9.38e-05	0.000287	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—SPP1—breast cancer	9.38e-05	0.000287	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—CXCL8—breast cancer	9.34e-05	0.000286	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ERBB3—breast cancer	9.28e-05	0.000284	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—FGFR2—breast cancer	9.26e-05	0.000284	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—NOTCH2—breast cancer	9.17e-05	0.000281	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—HSP90AA1—breast cancer	9.17e-05	0.000281	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—SMAD4—breast cancer	9.11e-05	0.000279	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—PIK3CD—breast cancer	9.1e-05	0.000278	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IGF1R—breast cancer	9.06e-05	0.000277	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—CXCL8—breast cancer	9.02e-05	0.000276	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—IL2—breast cancer	8.93e-05	0.000273	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—AGTR1—breast cancer	8.92e-05	0.000273	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PRL—breast cancer	8.92e-05	0.000273	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—HES1—breast cancer	8.9e-05	0.000272	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—TERT—breast cancer	8.89e-05	0.000272	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—NCOR1—breast cancer	8.85e-05	0.000271	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PLA2G4A—breast cancer	8.85e-05	0.000271	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ADAM10—breast cancer	8.79e-05	0.000269	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—STK11—breast cancer	8.79e-05	0.000269	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—FGF1—breast cancer	8.75e-05	0.000268	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CSF2—breast cancer	8.75e-05	0.000268	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—RAF1—breast cancer	8.73e-05	0.000267	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PLG—breast cancer	8.7e-05	0.000266	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—NRG1—breast cancer	8.69e-05	0.000266	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—FGFR1—breast cancer	8.64e-05	0.000264	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—H2AFX—breast cancer	8.62e-05	0.000264	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—IL2—breast cancer	8.62e-05	0.000264	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—AKT2—breast cancer	8.6e-05	0.000263	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—E2F1—breast cancer	8.56e-05	0.000262	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FGF10—breast cancer	8.56e-05	0.000262	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—PIK3CB—breast cancer	8.52e-05	0.000261	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—HIF1A—breast cancer	8.5e-05	0.00026	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—LEP—breast cancer	8.3e-05	0.000254	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—PIK3CD—breast cancer	8.26e-05	0.000253	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PDGFA—breast cancer	8.26e-05	0.000253	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CAV1—breast cancer	8.23e-05	0.000252	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—SPP1—breast cancer	8.23e-05	0.000252	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—CXCL8—breast cancer	8.19e-05	0.000251	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TGFBR2—breast cancer	8.14e-05	0.000249	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ERBB3—breast cancer	8.14e-05	0.000249	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—KDR—breast cancer	8.13e-05	0.000249	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—FGFR2—breast cancer	8.12e-05	0.000249	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ITPR1—breast cancer	8.01e-05	0.000245	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—STAT5A—breast cancer	7.95e-05	0.000243	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ERBB4—breast cancer	7.95e-05	0.000243	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MMP3—breast cancer	7.95e-05	0.000243	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—PIK3CB—breast cancer	7.93e-05	0.000243	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ESR1—breast cancer	7.93e-05	0.000243	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—FN1—breast cancer	7.83e-05	0.00024	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—IL2—breast cancer	7.83e-05	0.00024	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—TERT—breast cancer	7.8e-05	0.000239	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—NFKBIA—breast cancer	7.74e-05	0.000237	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—SMAD4—breast cancer	7.7e-05	0.000236	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—NOTCH1—breast cancer	7.66e-05	0.000234	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IGF1R—breast cancer	7.66e-05	0.000234	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—CXCL8—breast cancer	7.62e-05	0.000233	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—FGFR1—breast cancer	7.57e-05	0.000232	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—HES1—breast cancer	7.52e-05	0.00023	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—KIT—breast cancer	7.49e-05	0.000229	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—APC—breast cancer	7.49e-05	0.000229	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PIK3CG—breast cancer	7.49e-05	0.000229	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—NCOR1—breast cancer	7.48e-05	0.000229	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PLA2G4A—breast cancer	7.48e-05	0.000229	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—HIF1A—breast cancer	7.46e-05	0.000228	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—EGF—breast cancer	7.41e-05	0.000227	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FGF1—breast cancer	7.39e-05	0.000226	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CSF2—breast cancer	7.39e-05	0.000226	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—RAF1—breast cancer	7.38e-05	0.000226	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—NRG1—breast cancer	7.34e-05	0.000225	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—H2AFX—breast cancer	7.29e-05	0.000223	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—IL2—breast cancer	7.28e-05	0.000223	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—LEP—breast cancer	7.28e-05	0.000223	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—E2F1—breast cancer	7.24e-05	0.000221	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CAV1—breast cancer	7.21e-05	0.000221	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—PIK3CB—breast cancer	7.2e-05	0.00022	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—MAPK3—breast cancer	7.18e-05	0.00022	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—KDR—breast cancer	7.13e-05	0.000218	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—BRAF—breast cancer	7.04e-05	0.000216	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—SPP1—breast cancer	6.95e-05	0.000213	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ESR1—breast cancer	6.95e-05	0.000213	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—CXCL8—breast cancer	6.92e-05	0.000212	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ERBB3—breast cancer	6.88e-05	0.00021	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FGFR2—breast cancer	6.87e-05	0.00021	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—FN1—breast cancer	6.87e-05	0.00021	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IGF1—breast cancer	6.86e-05	0.00021	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—AKT2—breast cancer	6.86e-05	0.00021	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—EGFR—breast cancer	6.83e-05	0.000209	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—NFKBIA—breast cancer	6.78e-05	0.000208	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—NOTCH1—breast cancer	6.72e-05	0.000206	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—IL2—breast cancer	6.61e-05	0.000202	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TERT—breast cancer	6.59e-05	0.000202	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PIK3CD—breast cancer	6.59e-05	0.000202	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—APC—breast cancer	6.57e-05	0.000201	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PIK3CG—breast cancer	6.57e-05	0.000201	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—KIT—breast cancer	6.57e-05	0.000201	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—PIK3CA—breast cancer	6.52e-05	0.0002	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—SERPINE1—breast cancer	6.51e-05	0.000199	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—EGF—breast cancer	6.49e-05	0.000199	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—KRAS—breast cancer	6.45e-05	0.000197	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FGFR1—breast cancer	6.4e-05	0.000196	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—HIF1A—breast cancer	6.3e-05	0.000193	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—MAPK3—breast cancer	6.29e-05	0.000193	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—NOS3—breast cancer	6.22e-05	0.00019	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—BRAF—breast cancer	6.18e-05	0.000189	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—LEP—breast cancer	6.15e-05	0.000188	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CAV1—breast cancer	6.1e-05	0.000187	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—KDR—breast cancer	6.03e-05	0.000184	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IGF1—breast cancer	6.02e-05	0.000184	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—AKT2—breast cancer	6.01e-05	0.000184	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—EGFR—breast cancer	5.99e-05	0.000183	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—PIK3CA—breast cancer	5.92e-05	0.000181	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MDM2—breast cancer	5.9e-05	0.000181	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—RAF1—breast cancer	5.88e-05	0.00018	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ESR1—breast cancer	5.87e-05	0.00018	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—RELA—breast cancer	5.85e-05	0.000179	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—ERBB2—breast cancer	5.82e-05	0.000178	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FN1—breast cancer	5.8e-05	0.000178	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PIK3CD—breast cancer	5.78e-05	0.000177	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MTOR—breast cancer	5.74e-05	0.000176	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PIK3CB—breast cancer	5.74e-05	0.000176	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—NFKBIA—breast cancer	5.73e-05	0.000175	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—PIK3CA—breast cancer	5.72e-05	0.000175	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—SERPINE1—breast cancer	5.71e-05	0.000175	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—NOTCH1—breast cancer	5.68e-05	0.000174	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—KRAS—breast cancer	5.65e-05	0.000173	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PIK3CG—breast cancer	5.55e-05	0.00017	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—KIT—breast cancer	5.55e-05	0.00017	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—APC—breast cancer	5.55e-05	0.00017	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CXCL8—breast cancer	5.52e-05	0.000169	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—EGF—breast cancer	5.49e-05	0.000168	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—HRAS—breast cancer	5.48e-05	0.000168	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—NOS3—breast cancer	5.45e-05	0.000167	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CDKN1B—breast cancer	5.39e-05	0.000165	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—AKT1—breast cancer	5.33e-05	0.000163	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—MAPK3—breast cancer	5.32e-05	0.000163	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CASP3—breast cancer	5.28e-05	0.000162	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IL2—breast cancer	5.27e-05	0.000161	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—IL6—breast cancer	5.25e-05	0.000161	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—BRAF—breast cancer	5.22e-05	0.00016	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—PIK3CA—breast cancer	5.2e-05	0.000159	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MDM2—breast cancer	5.17e-05	0.000158	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—RAF1—breast cancer	5.16e-05	0.000158	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CCND1—breast cancer	5.14e-05	0.000157	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—RELA—breast cancer	5.13e-05	0.000157	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—JUN—breast cancer	5.13e-05	0.000157	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—ERBB2—breast cancer	5.1e-05	0.000156	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CTNNB1—breast cancer	5.09e-05	0.000156	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IGF1—breast cancer	5.08e-05	0.000156	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—AKT2—breast cancer	5.08e-05	0.000155	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—EGFR—breast cancer	5.06e-05	0.000155	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MTOR—breast cancer	5.03e-05	0.000154	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PIK3CB—breast cancer	5.03e-05	0.000154	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MMP9—breast cancer	4.99e-05	0.000153	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—CDKN1A—breast cancer	4.97e-05	0.000152	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PTEN—breast cancer	4.96e-05	0.000152	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PIK3CD—breast cancer	4.88e-05	0.000149	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MAPK8—breast cancer	4.85e-05	0.000149	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—AKT1—breast cancer	4.84e-05	0.000148	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CXCL8—breast cancer	4.84e-05	0.000148	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—PIK3CA—breast cancer	4.84e-05	0.000148	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—SERPINE1—breast cancer	4.83e-05	0.000148	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—HRAS—breast cancer	4.81e-05	0.000147	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—KRAS—breast cancer	4.78e-05	0.000146	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CDKN1B—breast cancer	4.72e-05	0.000145	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—AKT1—breast cancer	4.67e-05	0.000143	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CASP3—breast cancer	4.63e-05	0.000142	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IL2—breast cancer	4.62e-05	0.000141	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—NOS3—breast cancer	4.61e-05	0.000141	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—SRC—breast cancer	4.6e-05	0.000141	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—IL6—breast cancer	4.6e-05	0.000141	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CCND1—breast cancer	4.51e-05	0.000138	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—JUN—breast cancer	4.5e-05	0.000138	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—VEGFA—breast cancer	4.48e-05	0.000137	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CTNNB1—breast cancer	4.46e-05	0.000137	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—STAT3—breast cancer	4.44e-05	0.000136	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—PIK3CA—breast cancer	4.39e-05	0.000134	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MMP9—breast cancer	4.38e-05	0.000134	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MDM2—breast cancer	4.37e-05	0.000134	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—CDKN1A—breast cancer	4.36e-05	0.000133	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—RAF1—breast cancer	4.36e-05	0.000133	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PTEN—breast cancer	4.35e-05	0.000133	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—RELA—breast cancer	4.34e-05	0.000133	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—ERBB2—breast cancer	4.31e-05	0.000132	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MAPK8—breast cancer	4.26e-05	0.00013	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MTOR—breast cancer	4.25e-05	0.00013	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PIK3CB—breast cancer	4.25e-05	0.00013	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—AKT1—breast cancer	4.24e-05	0.00013	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MAPK3—breast cancer	4.24e-05	0.00013	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—MYC—breast cancer	4.12e-05	0.000126	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—TGFB1—breast cancer	4.11e-05	0.000126	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CXCL8—breast cancer	4.09e-05	0.000125	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—HRAS—breast cancer	4.06e-05	0.000124	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—SRC—breast cancer	4.03e-05	0.000123	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—EGFR—breast cancer	4.03e-05	0.000123	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CDKN1B—breast cancer	3.99e-05	0.000122	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—AKT1—breast cancer	3.95e-05	0.000121	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—VEGFA—breast cancer	3.93e-05	0.00012	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CASP3—breast cancer	3.91e-05	0.00012	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IL2—breast cancer	3.91e-05	0.00012	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—STAT3—breast cancer	3.89e-05	0.000119	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—IL6—breast cancer	3.89e-05	0.000119	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—KRAS—breast cancer	3.81e-05	0.000117	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CCND1—breast cancer	3.81e-05	0.000117	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—JUN—breast cancer	3.8e-05	0.000116	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CTNNB1—breast cancer	3.77e-05	0.000115	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MAPK3—breast cancer	3.72e-05	0.000114	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MMP9—breast cancer	3.7e-05	0.000113	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—CDKN1A—breast cancer	3.68e-05	0.000113	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PTEN—breast cancer	3.68e-05	0.000113	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—MYC—breast cancer	3.62e-05	0.000111	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—TGFB1—breast cancer	3.61e-05	0.00011	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MAPK8—breast cancer	3.6e-05	0.00011	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—AKT1—breast cancer	3.59e-05	0.00011	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—EGFR—breast cancer	3.54e-05	0.000108	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—PIK3CA—breast cancer	3.5e-05	0.000107	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—SRC—breast cancer	3.41e-05	0.000104	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—TP53—breast cancer	3.39e-05	0.000104	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—KRAS—breast cancer	3.34e-05	0.000102	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—VEGFA—breast cancer	3.32e-05	0.000102	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—STAT3—breast cancer	3.29e-05	0.000101	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—HRAS—breast cancer	3.24e-05	9.91e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MAPK3—breast cancer	3.14e-05	9.61e-05	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—IL6—breast cancer	3.1e-05	9.48e-05	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—PIK3CA—breast cancer	3.07e-05	9.39e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—MYC—breast cancer	3.06e-05	9.35e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TGFB1—breast cancer	3.05e-05	9.33e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—EGFR—breast cancer	2.99e-05	9.15e-05	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—TP53—breast cancer	2.97e-05	9.09e-05	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—AKT1—breast cancer	2.86e-05	8.75e-05	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—HRAS—breast cancer	2.84e-05	8.69e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—KRAS—breast cancer	2.82e-05	8.64e-05	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—IL6—breast cancer	2.72e-05	8.32e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—PIK3CA—breast cancer	2.59e-05	7.94e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TP53—breast cancer	2.51e-05	7.68e-05	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—AKT1—breast cancer	2.51e-05	7.67e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—HRAS—breast cancer	2.4e-05	7.34e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—IL6—breast cancer	2.3e-05	7.03e-05	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—AKT1—breast cancer	2.12e-05	6.48e-05	CbGpPWpGaD
